Rigel Pharmaceuticals (RIGL) Competitors

$30.45 -1.47 (-4.61%)

As of 12:13 PM Eastern

RIGL vs. INVA, NVAX, ZBIO, MNKD, and GERN

Should you buy Rigel Pharmaceuticals stock or one of its competitors? MarketBeat compares Rigel Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rigel Pharmaceuticals include Innoviva (INVA), Novavax (NVAX), Zenas BioPharma (ZBIO), MannKind (MNKD), and Geron (GERN). These companies are all part of the "biotechnology" industry.

How does Rigel Pharmaceuticals compare to Innoviva?

Rigel Pharmaceuticals (NASDAQ:RIGL) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

66.2% of Rigel Pharmaceuticals shares are held by institutional investors. Comparatively, 99.1% of Innoviva shares are held by institutional investors. 10.5% of Rigel Pharmaceuticals shares are held by insiders. Comparatively, 2.0% of Innoviva shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Rigel Pharmaceuticals has a beta of 1.21, meaning that its stock price is 21% more volatile than the broader market. Comparatively, Innoviva has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market.

In the previous week, Rigel Pharmaceuticals had 7 more articles in the media than Innoviva. MarketBeat recorded 12 mentions for Rigel Pharmaceuticals and 5 mentions for Innoviva. Innoviva's average media sentiment score of 0.82 beat Rigel Pharmaceuticals' score of -0.16 indicating that Innoviva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rigel Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Innoviva	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Rigel Pharmaceuticals currently has a consensus target price of $54.50, indicating a potential upside of 78.98%. Innoviva has a consensus target price of $36.20, indicating a potential upside of 63.99%. Given Rigel Pharmaceuticals' higher possible upside, research analysts plainly believe Rigel Pharmaceuticals is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Rigel Pharmaceuticals has a net margin of 121.50% compared to Innoviva's net margin of 119.89%. Rigel Pharmaceuticals' return on equity of 47.99% beat Innoviva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	121.50%	47.99%	32.40%
Innoviva	119.89%	33.33%	22.67%

Rigel Pharmaceuticals has higher earnings, but lower revenue than Innoviva. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$294.28M	1.91	$367.02M	$18.72	1.63
Innoviva	$411.33M	3.96	$271.17M	$6.01	3.67

Summary

Rigel Pharmaceuticals beats Innoviva on 9 of the 16 factors compared between the two stocks.

How does Rigel Pharmaceuticals compare to Novavax?

Novavax (NASDAQ:NVAX) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

Novavax presently has a consensus target price of $12.13, indicating a potential upside of 32.85%. Rigel Pharmaceuticals has a consensus target price of $54.50, indicating a potential upside of 78.98%. Given Rigel Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Rigel Pharmaceuticals is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	4 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.10
Rigel Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

53.0% of Novavax shares are owned by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 1.0% of Novavax shares are owned by company insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Novavax has a beta of 2.37, suggesting that its stock price is 137% more volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market.

Novavax has higher revenue and earnings than Rigel Pharmaceuticals. Novavax is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.34	$440.30M	-$0.58	N/A
Rigel Pharmaceuticals	$294.28M	1.91	$367.02M	$18.72	1.63

Rigel Pharmaceuticals has a net margin of 121.50% compared to Novavax's net margin of -14.73%. Rigel Pharmaceuticals' return on equity of 47.99% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
Rigel Pharmaceuticals	121.50%	47.99%	32.40%

In the previous week, Novavax had 7 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 19 mentions for Novavax and 12 mentions for Rigel Pharmaceuticals. Novavax's average media sentiment score of 0.76 beat Rigel Pharmaceuticals' score of -0.16 indicating that Novavax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	10 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Rigel Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Rigel Pharmaceuticals beats Novavax on 10 of the 16 factors compared between the two stocks.

How does Rigel Pharmaceuticals compare to Zenas BioPharma?

Zenas BioPharma (NASDAQ:ZBIO) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.

In the previous week, Rigel Pharmaceuticals had 3 more articles in the media than Zenas BioPharma. MarketBeat recorded 12 mentions for Rigel Pharmaceuticals and 9 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 1.05 beat Rigel Pharmaceuticals' score of -0.16 indicating that Zenas BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas BioPharma	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rigel Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Zenas BioPharma has a beta of -0.61, meaning that its share price is 161% less volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market.

Zenas BioPharma presently has a consensus target price of $44.29, indicating a potential upside of 142.26%. Rigel Pharmaceuticals has a consensus target price of $54.50, indicating a potential upside of 78.98%. Given Zenas BioPharma's stronger consensus rating and higher probable upside, research analysts plainly believe Zenas BioPharma is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44
Rigel Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Rigel Pharmaceuticals has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10M	104.87	-$377.74M	-$7.81	N/A
Rigel Pharmaceuticals	$294.28M	1.91	$367.02M	$18.72	1.63

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 22.0% of Zenas BioPharma shares are owned by insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Rigel Pharmaceuticals has a net margin of 121.50% compared to Zenas BioPharma's net margin of 0.00%. Rigel Pharmaceuticals' return on equity of 47.99% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-112.13%	-76.14%
Rigel Pharmaceuticals	121.50%	47.99%	32.40%

Summary

Rigel Pharmaceuticals beats Zenas BioPharma on 10 of the 16 factors compared between the two stocks.

How does Rigel Pharmaceuticals compare to MannKind?

Rigel Pharmaceuticals (NASDAQ:RIGL) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.

Rigel Pharmaceuticals has higher earnings, but lower revenue than MannKind. MannKind is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$294.28M	1.91	$367.02M	$18.72	1.63
MannKind	$348.97M	2.73	$5.86M	-$0.07	N/A

Rigel Pharmaceuticals has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market. Comparatively, MannKind has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market.

Rigel Pharmaceuticals currently has a consensus target price of $54.50, indicating a potential upside of 78.98%. MannKind has a consensus target price of $8.84, indicating a potential upside of 186.67%. Given MannKind's stronger consensus rating and higher possible upside, analysts plainly believe MannKind is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Rigel Pharmaceuticals has a net margin of 121.50% compared to MannKind's net margin of -6.63%. Rigel Pharmaceuticals' return on equity of 47.99% beat MannKind's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	121.50%	47.99%	32.40%
MannKind	-6.63%	-11.21%	-3.92%

In the previous week, Rigel Pharmaceuticals had 4 more articles in the media than MannKind. MarketBeat recorded 12 mentions for Rigel Pharmaceuticals and 8 mentions for MannKind. MannKind's average media sentiment score of 0.36 beat Rigel Pharmaceuticals' score of -0.16 indicating that MannKind is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rigel Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
MannKind	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

66.2% of Rigel Pharmaceuticals shares are held by institutional investors. Comparatively, 49.6% of MannKind shares are held by institutional investors. 10.5% of Rigel Pharmaceuticals shares are held by insiders. Comparatively, 2.6% of MannKind shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Rigel Pharmaceuticals beats MannKind on 10 of the 16 factors compared between the two stocks.

How does Rigel Pharmaceuticals compare to Geron?

Rigel Pharmaceuticals (NASDAQ:RIGL) and Geron (NASDAQ:GERN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.

Rigel Pharmaceuticals has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$294.28M	1.91	$367.02M	$18.72	1.63
Geron	$183.88M	4.59	-$83.50M	-$0.11	N/A

Rigel Pharmaceuticals has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market. Comparatively, Geron has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

Rigel Pharmaceuticals currently has a consensus target price of $54.50, indicating a potential upside of 78.98%. Geron has a consensus target price of $2.50, indicating a potential upside of 90.11%. Given Geron's higher possible upside, analysts plainly believe Geron is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Geron	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Rigel Pharmaceuticals has a net margin of 121.50% compared to Geron's net margin of -35.48%. Rigel Pharmaceuticals' return on equity of 47.99% beat Geron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	121.50%	47.99%	32.40%
Geron	-35.48%	-23.31%	-10.08%

In the previous week, Rigel Pharmaceuticals had 3 more articles in the media than Geron. MarketBeat recorded 12 mentions for Rigel Pharmaceuticals and 9 mentions for Geron. Geron's average media sentiment score of 0.85 beat Rigel Pharmaceuticals' score of -0.16 indicating that Geron is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rigel Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Geron	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

66.2% of Rigel Pharmaceuticals shares are held by institutional investors. Comparatively, 73.7% of Geron shares are held by institutional investors. 10.5% of Rigel Pharmaceuticals shares are held by insiders. Comparatively, 1.7% of Geron shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Rigel Pharmaceuticals beats Geron on 12 of the 16 factors compared between the two stocks.

Get Rigel Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RIGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RIGL vs. The Competition

Export

Metric	Rigel Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$563.33M	$2.99B	$6.24B	$12.27B
Dividend Yield	N/A	1.96%	2.80%	5.35%
P/E Ratio	1.63	18.10	20.39	25.30
Price / Sales	1.91	261.46	539.22	73.02
Price / Cash	4.77	57.78	43.26	56.33
Price / Book	1.41	4.32	9.83	6.90
Net Income	$367.02M	$72.19M	$3.55B	$333.62M
7 Day Performance	16.94%	-2.20%	0.73%	-0.15%
1 Month Performance	-5.02%	-2.58%	-0.59%	1.68%
1 Year Performance	54.26%	41.31%	36.42%	32.68%

Rigel Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RIGL Rigel Pharmaceuticals	2.8279 of 5 stars	$30.45 -4.6%	$54.50 +79.0%	+74.6%	$563.33M	$294.28M	1.63	160	Analyst Forecast
INVA Innoviva	4.1108 of 5 stars	$22.52 -1.6%	$36.20 +60.7%	+26.9%	$1.70B	$411.33M	3.75	100
NVAX Novavax	2.1198 of 5 stars	$9.50 -6.0%	$12.13 +27.6%	+56.9%	$1.66B	$1.12B	N/A	1,990	Gap Down High Trading Volume
ZBIO Zenas BioPharma	3.555 of 5 stars	$20.40 +3.9%	$44.14 +116.4%	+117.7%	$1.13B	$10M	N/A	N/A	Earnings Report Analyst Forecast
MNKD MannKind	3.7235 of 5 stars	$3.36 -4.5%	$8.84 +163.2%	-29.5%	$1.09B	$348.97M	N/A	400

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RIGL) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rigel Pharmaceuticals (RIGL) Competitors

RIGL vs. INVA, NVAX, ZBIO, MNKD, and GERN

How does Rigel Pharmaceuticals compare to Innoviva?

Summary

How does Rigel Pharmaceuticals compare to Novavax?

Summary

How does Rigel Pharmaceuticals compare to Zenas BioPharma?

Summary

How does Rigel Pharmaceuticals compare to MannKind?

Summary

How does Rigel Pharmaceuticals compare to Geron?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RIGL vs. The Competition

Rigel Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rigel Pharmaceuticals (RIGL) Competitors

RIGL vs. INVA, NVAX, ZBIO, MNKD, and GERN

How does Rigel Pharmaceuticals compare to Innoviva?

Do institutionals & insiders hold more shares of RIGL or INVA?

Which has more risk & volatility, RIGL or INVA?

Does the media refer more to RIGL or INVA?

Do analysts rate RIGL or INVA?

Is RIGL or INVA more profitable?

Which has stronger earnings & valuation, RIGL or INVA?

Summary

How does Rigel Pharmaceuticals compare to Novavax?

Do analysts prefer NVAX or RIGL?

Do insiders and institutionals believe in NVAX or RIGL?

Which has more risk & volatility, NVAX or RIGL?

Which has preferable valuation & earnings, NVAX or RIGL?

Is NVAX or RIGL more profitable?

Does the media prefer NVAX or RIGL?

Summary

How does Rigel Pharmaceuticals compare to Zenas BioPharma?

Does the media favor ZBIO or RIGL?

Which has more volatility and risk, ZBIO or RIGL?

Do analysts prefer ZBIO or RIGL?

Which has better valuation and earnings, ZBIO or RIGL?

Do institutionals and insiders believe in ZBIO or RIGL?

Is ZBIO or RIGL more profitable?

Summary

How does Rigel Pharmaceuticals compare to MannKind?

Which has stronger earnings & valuation, RIGL or MNKD?

Which has more risk & volatility, RIGL or MNKD?

Do analysts recommend RIGL or MNKD?

Is RIGL or MNKD more profitable?

Does the media refer more to RIGL or MNKD?

Do insiders & institutionals believe in RIGL or MNKD?

Summary

How does Rigel Pharmaceuticals compare to Geron?

Which has stronger earnings & valuation, RIGL or GERN?

Which has more risk & volatility, RIGL or GERN?

Do analysts recommend RIGL or GERN?

Is RIGL or GERN more profitable?

Does the media refer more to RIGL or GERN?

Do insiders & institutionals believe in RIGL or GERN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RIGL vs. The Competition

Rigel Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools